[Paris, France – May 19, 2023] CorFlow Therapeutics AG, a clinical-stage company that has developed the world’s first combined system for diagnostic assessment and therapy delivery to address coronary microvascular obstruction (MVO), has announced the interim positive results of its MOCA I (Microvascular Obstruction with CoFI System Assessment) study at EuroPCR in Paris, France.
BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the FDA has designated the company’s CoFI (Controlled Flow Infusion) System as a “Breakthrough Device” with a broad indication-for-use statement: “The CoFI System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a platform for controlled infusion of therapeutic agents into the microcirculation with or without vessel occlusion.”
BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the company has completed the 2nd close of its Seed+ financing round.
The CoFI-System is not approved in the United States of America. It is an investigational device limited by federal law to investigational use and is not available for commercial distribution.
VAT:CHE 320.873.257 MWST
© 2023 Corflow. All Rights Reserved.
